Widespread use of PCV13, which covers additional serotypes ... After the introduction of pneumococcal conjugate vaccine (PCV)-7, emergence of non-PCV7 serotypes, especially 19A, is prominent ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

The 15-valent conjugate vaccine was at least as effective ... to steal a march on Pfizer in the large paediatric pneumococcal vaccine category, as its rival is around a year away from reporting ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31 with the first subjects now dosed in ...

The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of efforts to protect infants ...

“Invasive pneumococcal disease and pneumococcal ... 18 years of age and older who had not previously received a pneumococcal vaccine. The recommendation is also supported by results from the ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products ...

recommended the approval of CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...